仿制药-话题@MedSci

#仿制药#

261篇内容 | 5550人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1261434, encodeId=686112614343e, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Clover制药在中国启动依那西普生物仿制药的I期试验, objectType=article, longId=145739, objectId=a66f145e39d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a66f145e39d1, replyNumber=0, likeNumber=79, createdTime=2018-08-04, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a66f145e39d1, moduleTitle=Clover制药在中国启动依那西普生物仿制药的I期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a66f145e39d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261433, encodeId=41b01261433e4, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药无法替换原研谁说的？, objectType=article, longId=145719, objectId=44f0145e1946, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44f0145e1946, replyNumber=0, likeNumber=106, createdTime=2018-08-04, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44f0145e1946, moduleTitle=仿制药无法替换原研谁说的？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44f0145e1946)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261432, encodeId=e15b1261432bf, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=辉瑞Trazimera（Herceptin生物仿制药）已获欧盟委员会的批准, objectType=article, longId=145635, objectId=848014563563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=848014563563, replyNumber=0, likeNumber=60, createdTime=2018-08-03, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=848014563563, moduleTitle=辉瑞Trazimera（Herceptin生物仿制药）已获欧盟委员会的批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=848014563563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261431, encodeId=2a6c126143116, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药一致性评价时间节点将至 289种基本药物将何去何从？, objectType=article, longId=145528, objectId=0895145528ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0895145528ae, replyNumber=0, likeNumber=61, createdTime=2018-08-01, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0895145528ae, moduleTitle=仿制药一致性评价时间节点将至 289种基本药物将何去何从？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0895145528ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261430, encodeId=b223126143095, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Sandoz获得欧洲委员会对生物仿制药Hyrimoz的批准, objectType=article, longId=145409, objectId=aba8145409dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aba8145409dd, replyNumber=0, likeNumber=54, createdTime=2018-07-30, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aba8145409dd, moduleTitle=Sandoz获得欧洲委员会对生物仿制药Hyrimoz的批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aba8145409dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261429, encodeId=07e51261429be, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=EMA支持批准Amgen的Neulasta的第一个生物仿制药版本, objectType=article, longId=145379, objectId=2d8b1453e9a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d8b1453e9a0, replyNumber=0, likeNumber=60, createdTime=2018-07-30, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d8b1453e9a0, moduleTitle=EMA支持批准Amgen的Neulasta的第一个生物仿制药版本, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d8b1453e9a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261428, encodeId=867012614287a, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=药价太高怎么办？美国：进口国外仿制药增加市场竞争, objectType=article, longId=145355, objectId=4e341453557c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e341453557c, replyNumber=0, likeNumber=64, createdTime=2018-07-29, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e341453557c, moduleTitle=药价太高怎么办？美国：进口国外仿制药增加市场竞争, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e341453557c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261427, encodeId=8eb4126142ee7, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=让老百姓用得起好药，上海全力推进仿制药质量疗效一致性评价, objectType=article, longId=145155, objectId=23d51451551b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23d51451551b, replyNumber=0, likeNumber=71, createdTime=2018-07-27, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23d51451551b, moduleTitle=让老百姓用得起好药，上海全力推进仿制药质量疗效一致性评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23d51451551b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261426, encodeId=ea9a12614262c, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=辉瑞生物仿制药Nivestym获FDA批准用于治疗中性粒细胞减少症, objectType=article, longId=145075, objectId=ca0b1450e5d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca0b1450e5d7, replyNumber=0, likeNumber=65, createdTime=2018-07-25, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca0b1450e5d7, moduleTitle=辉瑞生物仿制药Nivestym获FDA批准用于治疗中性粒细胞减少症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca0b1450e5d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261425, encodeId=d80f12614255f, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Semin Arthritis Rheu：从原研药转为生物仿制药依那西普（SB4）的接受率和所涉及的社会学因素, objectType=article, longId=145029, objectId=be031450298b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be031450298b, replyNumber=0, likeNumber=19, createdTime=2018-07-25, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be031450298b, moduleTitle=Semin Arthritis Rheu：从原研药转为生物仿制药依那西普（SB4）的接受率和所涉及的社会学因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be031450298b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261424, encodeId=a4b0126142493, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=大批印度仿制药或将涌入中国, objectType=article, longId=144827, objectId=327714482e93, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=327714482e93, replyNumber=0, likeNumber=55, createdTime=2018-07-22, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=327714482e93, moduleTitle=大批印度仿制药或将涌入中国, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=327714482e93)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261423, encodeId=55c5126142325, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=优质仿制药，在辽宁要爆发了, objectType=article, longId=144591, objectId=8d73144591dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d73144591dc, replyNumber=0, likeNumber=82, createdTime=2018-07-19, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d73144591dc, moduleTitle=优质仿制药，在辽宁要爆发了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d73144591dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261422, encodeId=b3221261422da, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=国家药监局：境外开展仿制药研发，数据完整可在中国注册申报, objectType=article, longId=143979, objectId=a9a61439e95f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9a61439e95f, replyNumber=0, likeNumber=63, createdTime=2018-07-12, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9a61439e95f, moduleTitle=国家药监局：境外开展仿制药研发，数据完整可在中国注册申报, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9a61439e95f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261421, encodeId=b49612614212f, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药大潮来临医药代表未来在哪里, objectType=article, longId=142942, objectId=f6ff142942b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6ff142942b8, replyNumber=0, likeNumber=83, createdTime=2018-07-12, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6ff142942b8, moduleTitle=仿制药大潮来临医药代表未来在哪里, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6ff142942b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261420, encodeId=71071261420a8, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=《药神》里的进口抗癌药会降价吗？国产仿制药通过一致性评价, objectType=article, longId=142678, objectId=ad321426e827, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad321426e827, replyNumber=0, likeNumber=52, createdTime=2018-07-08, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad321426e827, moduleTitle=《药神》里的进口抗癌药会降价吗？国产仿制药通过一致性评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad321426e827)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261419, encodeId=ddb31261419d9, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=36种谈判药品仿制药纳入北京医保, objectType=article, longId=142543, objectId=bff0142543c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bff0142543c0, replyNumber=0, likeNumber=64, createdTime=2018-07-07, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bff0142543c0, moduleTitle=36种谈判药品仿制药纳入北京医保, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bff0142543c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261418, encodeId=539e126141870, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=从《我不是药神》看国产仿制药十年政策演变, objectType=article, longId=142488, objectId=dc2d142488d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc2d142488d7, replyNumber=0, likeNumber=43, createdTime=2018-07-06, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc2d142488d7, moduleTitle=从《我不是药神》看国产仿制药十年政策演变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc2d142488d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261417, encodeId=e26d126141e68, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=《我不是药神》上映的背后：印度仿制药为何如此低廉, objectType=article, longId=142443, objectId=cd2e1424433f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd2e1424433f, replyNumber=0, likeNumber=64, createdTime=2018-07-06, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd2e1424433f, moduleTitle=《我不是药神》上映的背后：印度仿制药为何如此低廉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd2e1424433f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261416, encodeId=912a126141641, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=安进公司宣布生物仿制药ABP 710的III期临床研究结果, objectType=article, longId=141928, objectId=2c18141928fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c18141928fb, replyNumber=0, likeNumber=91, createdTime=2018-06-30, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c18141928fb, moduleTitle=安进公司宣布生物仿制药ABP 710的III期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c18141928fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261415, encodeId=aa1f126141540, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=为“山寨”“侵权”开绿灯印度如何将仿制药做成千亿大生意, objectType=article, longId=140032, objectId=e177140032d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e177140032d3, replyNumber=0, likeNumber=95, createdTime=2018-06-07, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e177140032d3, moduleTitle=为“山寨”“侵权”开绿灯印度如何将仿制药做成千亿大生意, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e177140032d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

仿制药

2020-05-29

zhouqu_8 (审核中...)

前往app查看评论内容

#仿制药#

Clover制药在中国启动依那西普生物仿制药的I期试验

2018-08-04

zhouqu_8 (审核中...)

前往app查看评论内容

#仿制药#

仿制药无法替换原研谁说的？

2018-08-04

zhouqu_8 (审核中...)

前往app查看评论内容

#仿制药#

辉瑞Trazimera（Herceptin生物仿制药）已获欧盟委员会的批准

2018-08-03

zhouqu_8 (审核中...)

前往app查看评论内容

#仿制药#

仿制药一致性评价时间节点将至 289种基本药物将何去何从？

2018-08-01

zhouqu_8 (审核中...)

前往app查看评论内容

#仿制药#

Sandoz获得欧洲委员会对生物仿制药Hyrimoz的批准

2018-07-30

drwjr (审核中...)

前往app查看评论内容

#仿制药#

EMA支持批准Amgen的Neulasta的第一个生物仿制药版本

2018-07-30

drwjr (审核中...)

前往app查看评论内容

#仿制药#

药价太高怎么办？美国：进口国外仿制药增加市场竞争

2018-07-29

drwjr (审核中...)

前往app查看评论内容

#仿制药#

让老百姓用得起好药，上海全力推进仿制药质量疗效一致性评价

2018-07-27

drwjr (审核中...)

前往app查看评论内容

#仿制药#

辉瑞生物仿制药Nivestym获FDA批准用于治疗中性粒细胞减少症

2018-07-25

drwjr (审核中...)

前往app查看评论内容

#仿制药#

Semin Arthritis Rheu：从原研药转为生物仿制药依那西普（SB4）的接受率和所涉及的社会学因素

2018-07-25

drwjr (审核中...)

前往app查看评论内容

#仿制药#

大批印度仿制药或将涌入中国

2018-07-22

drwjr (审核中...)

前往app查看评论内容

#仿制药#

优质仿制药，在辽宁要爆发了

2018-07-19

drwjr (审核中...)

前往app查看评论内容

#仿制药#

国家药监局：境外开展仿制药研发，数据完整可在中国注册申报

2018-07-12

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药大潮来临医药代表未来在哪里

2018-07-12

drwjr (审核中...)

前往app查看评论内容

#仿制药#

《药神》里的进口抗癌药会降价吗？国产仿制药通过一致性评价

2018-07-08

drwjr (审核中...)

前往app查看评论内容

#仿制药#

36种谈判药品仿制药纳入北京医保

2018-07-07

drwjr (审核中...)

前往app查看评论内容

#仿制药#

从《我不是药神》看国产仿制药十年政策演变

2018-07-06

drwjr (审核中...)

前往app查看评论内容

#仿制药#

《我不是药神》上映的背后：印度仿制药为何如此低廉

2018-07-06

drwjr (审核中...)

前往app查看评论内容

#仿制药#

安进公司宣布生物仿制药ABP 710的III期临床研究结果

2018-06-30

drwjr (审核中...)

前往app查看评论内容

#仿制药#

为“山寨”“侵权”开绿灯印度如何将仿制药做成千亿大生意

2018-06-07

科室
- - 订阅+
  - 更多科室
工具
服务